Yael P Mosse

Yael
 
P
 
Mosse
, 
M.D.
Email: 
mosse@email.chop.edu
Address: 
The Children's Hospital of Philadelphia Colket Translational Research Building, Office 3056 3501 Civic Center Blvd.
215-590-0965
Appointments
Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine (2006– present)
Education
M.D., Sackler School of Medicine, Tel Aviv, Israel (1997)
B.A., Smith College (1993)
B.A., Hebrew University, Jerusalem, Israel (1992)
Selected Publications
Mossé Yael P, Lipsitz Emily, Fox Elizabeth, Teachey David T, Maris John M, Weigel Brenda, Adamson Peter C, Ingle Mark A, Ahern Charlotte H, Blaney Susan M. Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol 18(21) . 2012 Nov:6058-64.
Carpenter E L, Haglund E A, Mace E M, Deng D, Martinez D, Wood A C, Chow A K, Weiser D A, Belcastro L T, Winter C, Bresler S C, Asgharzadeh S, Seeger R C, Zhao H, Guo R, Christensen J G, Orange J S, Pawel B R, Lemmon M A, Mossé Y P. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.. Oncogene. Vol 31(46) . 2012 Nov:4859-67.
Carpenter Erica L, Mossé Yael P. Targeting ALK in neuroblastoma--preclinical and clinical advancements.. Nature Reviews Clinical Oncology. Vol 9(7) . 2012 Jul:391-9.
DuBois Steven G, Chesler Louis, Groshen Susan, Hawkins Randall, Goodarzian Fariba, Shimada Hiroyuki, Yanik Greg, Tagen Michael, Stewart Clinton, Mosse Yael P, Maris John M, Tsao-Wei Denice, Marachelian Araz, Villablanca Judith G, Matthay Katherine K. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol 18(9) . 2012 May:2679-86.
Bosse Kristopher R, Diskin Sharon J, Cole Kristina A, Wood Andrew C, Schnepp Robert W, Norris Geoffrey, Nguyen Le B, Jagannathan Jayanti, Laquaglia Michael, Winter Cynthia, Diamond Maura, Hou Cuiping, Attiyeh Edward F, Mosse Yael P, Pineros Vanessa, Dizin Eva, Zhang Yongqiang, Asgharzadeh Shahab, Seeger Robert C, Capasso Mario, Pawel Bruce R, Devoto Marcella, Hakonarson Hakon, Rappaport Eric F, Irminger-Finger Irmgard, Maris John M. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.. Cancer research. Vol 72(8) . 2012 Apr:2068-78.
Y.P. Mosse, F.M. Balis, M.S. Lim, J Laliberte, S Voss, E Fox, R Bagatell, B.J. Weigel, P.A. Adamson, M.A. Ingle, C.H. Ahern, S.M. Blaney. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors: A Children?s Oncology Group Phase 1 Study. ASCO Annual Meeting. 2012.
D.A. Weiser, S.C. Bresler, M. Laudenslager, E.F. Rappaport, E.L. Carpenter, M. Hogarty, P.W. McGrady, W.B. London, M.A. Lemmon, Y.P. Mosse. ALK-based therapeutic stratification of patients with neuroblastoma. Advances in Neuroblastoma Research (ANR) Meeting. 2012.
E.L. Carpenter, D Deng, E.A. Haglund, L. Belcastro, R. Metcalfe-Klaw, H. Maamar, A. Raj, J.G. Christensen, Y.P. Mosse. Mechanisms of acquired resistance in crizotinib-treated neuroblastoma. Advances in Neuroblastoma Research (ANR) Meeting. 2012.
Y.P. Mosse, F.M. Balis, M.S. Lim, J Laliberte, S Voss, E Fox, R Bagatell, B.J. Weigel, P.A. Adamson, M.A. Ingle, C.H. Ahern, S.M. Blaney. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors: A Children?s Oncology Group Phase 1 Study. Advances in Neuroblastoma Research (ANR) Meeting. 2012.
A.C. Wood, M. Laudenslager, K. Krytska, M. Sarmady, J. Perin, E.F. Rappaport, J.M. Maris, M. Devoto, Y.P. Mosse. Identification of a new hereditary neuroblastoma predisposition locus at chromosome 2p25. Advances in Neuroblastoma Research (ANR) Meeting. 2012.